274 related articles for article (PubMed ID: 21199319)
21. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
Bellows BK; Dahal A; Jiao T; Biskupiak J
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):153-64. PubMed ID: 22509775
[TBL] [Abstract][Full Text] [Related]
22. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine.
Zhao Y; Chen SY; Wu N; Fraser KA; Boulanger L
Pain Pract; 2011; 11(4):381-91. PubMed ID: 21199311
[TBL] [Abstract][Full Text] [Related]
23. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
Kirson NY; Ivanova JI; Birnbaum HG; Wei R; Kantor E; Puenpatom RA; Ben-Joseph RH; Summers KH
J Med Econ; 2010; 13(3):482-91. PubMed ID: 20684669
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
Choy E; Richards S; Bowrin K; Watson P; Lloyd A; Sadosky A; Zlateva G
Curr Med Res Opin; 2010 Apr; 26(4):965-75. PubMed ID: 20178405
[TBL] [Abstract][Full Text] [Related]
25. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
[TBL] [Abstract][Full Text] [Related]
26. Duloxetine use in employees with low back pain: treatment patterns and direct and indirect costs.
Ivanova JI; Birnbaum HG; Kantor E; Schiller M; Swindle RW
Pain Med; 2014 Jun; 15(6):1015-26. PubMed ID: 24529260
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico.
Arreola Ornelas H; Rosado Buzzo A; García L; Dorantes Aguilar J; Contreras Hernández I; Mould Quevedo JF
Reumatol Clin; 2012; 8(3):120-7. PubMed ID: 22386298
[TBL] [Abstract][Full Text] [Related]
28. A systematic review of pharmacoeconomic studies for pregabalin.
Parker L; Huelin R; Khankhel Z; Wasiak R; Mould J
Pain Pract; 2015 Jan; 15(1):82-94. PubMed ID: 24815038
[TBL] [Abstract][Full Text] [Related]
29. Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia.
Kim SC; Landon JE; Lee YC
Arthritis Res Ther; 2015 Jan; 17(1):18. PubMed ID: 25627453
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine.
Cui Z; Faries DE; Shen W; Able SL; Novick D
J Med Econ; 2013; 16(5):623-32. PubMed ID: 23425292
[TBL] [Abstract][Full Text] [Related]
31. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Planas-Comes A
J Eval Clin Pract; 2012 Dec; 18(6):1170-9. PubMed ID: 21883712
[TBL] [Abstract][Full Text] [Related]
32. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
[TBL] [Abstract][Full Text] [Related]
33. Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine.
Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL
Am J Health Syst Pharm; 2013 Dec; 70(24):2207-17. PubMed ID: 24296843
[TBL] [Abstract][Full Text] [Related]
34. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial.
Luciano JV; D'Amico F; Cerdà-Lafont M; Peñarrubia-María MT; Knapp M; Cuesta-Vargas AI; Serrano-Blanco A; García-Campayo J
Arthritis Res Ther; 2014 Oct; 16(5):451. PubMed ID: 25270426
[TBL] [Abstract][Full Text] [Related]
35. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome.
Russell IJ; Crofford LJ; Leon T; Cappelleri JC; Bushmakin AG; Whalen E; Barrett JA; Sadosky A
Sleep Med; 2009 Jun; 10(6):604-10. PubMed ID: 19410509
[TBL] [Abstract][Full Text] [Related]
36. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia.
Pauer L; Winkelmann A; Arsenault P; Jespersen A; Whelan L; Atkinson G; Leon T; Zeiher B;
J Rheumatol; 2011 Dec; 38(12):2643-52. PubMed ID: 21965636
[TBL] [Abstract][Full Text] [Related]
37. Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies.
Zhao Y; Wu N; Chen S; Boulanger L; Police RL; Fraser K
Curr Med Res Opin; 2010 Sep; 26(9):2147-56. PubMed ID: 20662557
[TBL] [Abstract][Full Text] [Related]
38. Impact of a pregabalin step therapy policy among medicare advantage beneficiaries.
Suehs BT; Louder A; Udall M; Cappelleri JC; Joshi AV; Patel NC
Pain Pract; 2014 Jun; 14(5):419-26. PubMed ID: 23701733
[TBL] [Abstract][Full Text] [Related]
39. Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain.
Sun P; Zhao Y; Zhao Z; Bernauer M; Watson P
Pain Pract; 2012 Nov; 12(8):641-8. PubMed ID: 22335435
[TBL] [Abstract][Full Text] [Related]
40. Cost savings associated with early initiation of pregabalin in the management of peripheral neuropathic pain.
Pérez C; Navarro A; Saldaña MT; Figueras-Balsells M; Muñoz-Tudurí M; Rejas J
Clin J Pain; 2013 Jun; 29(6):471-7. PubMed ID: 23328322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
